Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease

作     者：Jorge-Luis Torres Ignacio Novo-Veleiro Laura Manzanedo Lucía Alvela-Suárez Ronald Macías Francisco-Javier Laso Miguel Marcos 

作者机构：Department of Internal MedicineUniversity Hospital of SalamancaInstitute of Biomedical Research of Salamanca-IBSAL Spanish Working Group on Alcohol and AlcoholismSpanish Society of Internal Medicine Department of Internal MedicineUniversity Hospital of Santiago de Compostela Department of Internal MedicineHM Rosaleda HospitalSantiago de Compostela Department of MedicineFaculty of MedicineUniversity of Salamanca 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2018年第24卷第36期

页      面：4104-4118页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by the Spanish Ministry of Science and Innovation,Instituto de Salud Carlos Ⅲ and the European Union FEDER funds,Una manera de hacer Europa,(No.PI16/01548 to Miguel Marcos and No.RD16/0017/0023 to Francisco-Javier Laso) Junta de Castilla y León GRS 1362/A/16 and INT/M/17/17 to Miguel Marcos and GRS 1587/A/17 to Jorge-Luis Torres 

主　　题：Alcohol use disorder Alcoholic liver disease Non-alcoholic fatty liver disease Steatosis Obesity miRNA Biomarkers 

摘      要：MicroRNAs(miRNAs) are small non-coding RNAs that regulate multiple physiological and pathological functions through the modulation of gene expression at the post-transcriptional level. Accumulating evidence has established a role for miRNAs in the development and pathogenesis of liver disease. Specifically, a large number of studies have assessed the role of miRNAsin alcoholic liver disease(ALD) and non-alcoholic fatty liver disease(NAFLD), two diseases that share common underlying mechanisms and pathological characteristics. The purpose of the current review is to summarize and update the body of literature investigating the role of miRNAs in liver disease. In addition, the potential use of miRNAs as biomarkers and/or therapeutic targets is discussed. Among all miRNAs analyzed, miR-34 a, miR-122 and miR-155 are most involved in the pathogenesis of NAFLD. Of note, these three miRNAs have also been implicated in ALD, reinforcing a common disease mechanism between these two entities and the pleiotropic effects of specific miRNAs. Currently, no single miRNA or panel of miRNAs has been identified for the detection of, or staging of ALD or NAFLD. While promising results have been shown in murine models, no therapeutic based-miRNA agents have been developed for use in humans with liver disease.